Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  • Michael S Binkley
  • M Shahzad Rauf
  • Sarah A Milgrom
  • Chelsea C Pinnix
  • Richard Tsang
  • Michael Dickinson
  • Andrea K Ng
  • Kenneth B Roberts
  • Sarah Gao
  • Alex Balogh
  • Umberto Ricardi
  • Mario Levis
  • Carla Casulo
  • Michael Stolten
  • Lena Specht
  • John P Plastaras
  • Christopher Wright
  • Christopher R Kelsey
  • Jessica L Brady
  • N George Mikhaeel
  • Bradford S Hoppe
  • Stephanie A Terezakis
  • Marco Picardi
  • Roberta Della Pepa
  • Youlia Kirova
  • Saad Akhtar
  • Irfan Maghfoor
  • Julie L Koenig
  • Christopher Jackson
  • Erin Song
  • Shuchi Sehgal
  • Ranjana H Advani
  • Yasodha Natkunam
  • Louis S Constine
  • Hans T Eich
  • Andrew Wirth
  • Richard T Hoppe
Vis graf over relationer

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ≥16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT+chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n = 257; 46.0%), CMT (n = 184; 32.9%), CT alone (n = 47; 8.4%), observation (n = 37; 6.6%), rituximab and RT (n = 19; 3.4%), and rituximab alone (n = 15; 2.7%). The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites >2 were associated with worse PFS (P < .05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly higher transformation rate in those with variant immunoarchitectural pattern (P = .049) and number of involved sites >2 (P = .0006). OS for patients with stage I-II NLPHL was excellent after all treatments.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind135
Udgave nummer26
Sider (fra-til)2365-2374
Antal sider10
ISSN0006-4971
DOI
StatusUdgivet - 25 jun. 2020

Bibliografisk note

© 2020 by The American Society of Hematology.

ID: 61016198